We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
101
Regeneron Pharmaceuticals
REGN
$70.9B
$8.26M 0.13%
+22,000
New +$7.4M
HCAT icon
102
Health Catalyst
HCAT
$160M
$7.79M 0.12%
224,508
+64,292
+40% +$2.13M
ONC
103
BeOne Medicines Ltd
ONC
$32.3B
$7.77M 0.12%
46,856
-25,244
-35% -$4.19M
SILK
104
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.43M 0.12%
183,896
+51,942
+39% +$1.82M
PHR icon
105
Phreesia
PHR
$659M
$7.22M 0.11%
271,045
+50,355
+23% +$1.39M
VEEV icon
106
Veeva Systems
VEEV
$32.4B
$7.16M 0.11%
50,884
– –
VCRA
107
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.31M 0.1%
304,143
+54,970
+22% +$1.21M
KZR
108
DELISTED
Kezar Life Sciences
KZR
$6.22M 0.1%
155,067
+32,015
+26% +$985K
AVTR icon
109
Avantor
AVTR
$7.33B
$5.71M 0.09%
314,566
+117,615
+60% +$1.87M
BMRN icon
110
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.68M 0.09%
+67,200
New +$5.08M
QGEN icon
111
Qiagen
QGEN
$8.4B
$5.44M 0.09%
151,687
-450,872
-75% -$16.8M
ZLAB icon
112
Zai Lab
ZLAB
$2.29B
$5.02M 0.08%
120,782
+90,782
+303% +$3.35M
SDC
113
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$4.63M 0.07%
530,230
+180,230
+51% +$1.8M
LVGO
114
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$4.58M 0.07%
182,574
+139,354
+322% +$3.33M
SGEN
115
DELISTED
Seagen Inc. Common Stock
SGEN
$4.27M 0.07%
37,400
-43,900
-54% -$4.66M
ABBV icon
116
AbbVie
ABBV
$448B
$3.76M 0.06%
+42,500
New +$3.53M
FIT
117
DELISTED
Fitbit, Inc. Class A common stock
FIT
$3.75M 0.06%
570,959
-2,088,985
-79% -$12.3M
ALKS icon
118
Alkermes
ALKS
$8.69B
$3.44M 0.05%
+168,400
New +$3.35M
QTNT
119
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.38M 0.05%
8,897
-9,800
-52% -$3.25M
MNTA
120
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.2M 0.05%
162,400
+112,400
+225% +$1.8M
MRK icon
121
Merck
MRK
$309B
$2.73M 0.04%
+31,440
New +$2.58M
SYNH
122
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$2.71M 0.04%
45,600
-16,400
-26% -$882K
PTCT icon
123
PTC Therapeutics
PTCT
$6.49B
$2.69M 0.04%
56,100
-25,100
-31% -$1.07M
CHRS icon
124
Coherus Oncology
CHRS
$219M
$2.67M 0.04%
148,500
-52,935
-26% -$976K
TEVA icon
125
Teva Pharmaceuticals
TEVA
$36.5B
$2.61M 0.04%
266,000
+116,000
+77% +$1.04M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.